ReviewDrug design, development and therapy2015
The role of taxanes in triple-negative breast cancer: literature review.
Review in Drug design, development and therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 78 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
78 citing papers in PubMed, 1 synthesis or guideline pooled it, 138 citations in OpenAlex.
- Does microtubule motor-mediated centrosomal dyshomeostasis confer chemoresistance in breast cancer?Journal of mammary gland biology and neoplasia · 2025Pooled it
- Precise Ratiometric Drug Delivery for the Treatment of Triple-Negative Breast Cancer.ACS nano · 2025Article
- The search for a TNBC vaccine: the guardian vaccine.Cancer biology & therapy · 2025Review
- The Marine Natural Compound Aplysinamisine I Selectively Induces Apoptosis and Exhibits Synergy with Taxol™ in Triple-Negative Breast Cancer Spheroids.Marine drugs · 2025Article
- Article
- Chemotherapy of breast cancer cells alters susceptibility to complement-mediated opsonization and killing.Medical oncology (Northwood, London, England) · 2025Article
- Targeting Triple-Negative Breast Cancer: Resistance Mechanisms and Therapeutic Advancements.Cancer medicine · 2025Review
- CARM1 regulates tubulin autoregulation through PI3KC2α R175 methylation.Cell communication and signaling : CCS · 2025Article
- TNBC response to paclitaxel phenocopies interferon response which reveals cell cycle-associated resistance mechanisms.Scientific reports · 2025Article
- Exploring the Regulatory Roles of miR-21, miR-15, and miR-let-7 in ABC Transporter-Mediated Chemoresistance: Implications for Breast Cancer Etiology and Treatment.Molecular biotechnology · 2025Article
- Docetaxel response in BRCA1,p53-deficient mammary tumor cells is affected by Huntingtin and BAP1.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Impact of Neoadjuvant Therapy on PD-L1 Expression in Triple-Negative Breast Cancer and Correlation with Clinicopathological Factors.Diagnostics (Basel, Switzerland) · 2024Article
- A Theoretical Study of the Interaction of PARP-1 with Natural and Synthetic Inhibitors: Advances in the Therapy of Triple-Negative Breast Cancer.Current issues in molecular biology · 2024Article
- An Investigation of In Vitro Anti-Cancer Efficacy of Dihydroartemisinin-Loaded Bovine Milk Exosomes Against Triple-Negative Breast Cancer.The AAPS journal · 2024Article
- TNBC response to paclitaxel phenocopies interferon response which reveals cell cycle-associated resistance mechanisms.bioRxiv : the preprint server for biology · 2024Article
- PTGER3 knockdown inhibits the vulnerability of triple-negative breast cancer to ferroptosis.Cancer science · 2024Article
- EMP2 Serves as a Functional Biomarker for Chemotherapy-Resistant Triple-Negative Breast Cancer.Cancers · 2024Article
- Basal-epithelial subpopulations underlie and predict chemotherapy resistance in triple-negative breast cancer.EMBO molecular medicine · 2024Article
- MLL1 regulates cytokine-driven cell migration and metastasis.Science advances · 2024Article
- TRF2 as novel marker of tumor response to taxane-based therapy: from mechanistic insight to clinical implication.Journal of experimental & clinical cancer research : CR · 2024Article
18 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer (BC) is the most frequent tumor worldwide. Triple-negative BCs are characterized by the negative estrogen and progesterone receptors and negative HER2, and represent 15% of all BCs. In this review, data on the use of taxanes in triple-negative BCs are analyzed, concluding they are effective in any clinical setting (neoadjuvant, adjuvant, and metastatic). Further, the role of nab-paclitaxel (formulation of albumin-bound paclitaxel) in these tumors is also evaluated. The available data show the clinical potential of nab-paclitaxel based combinations in terms of long-duration response, increased survival, and better quality of life of patients with triple-negative metastatic BC. The ongoing trials will give further information on the better management of this type of tumor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.